A new test for two blood cancers developed by a team at Washington University School of Medicine in St. Louis is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Service
A new test for two blood cancers – developed by a team at Washington University School of Medicine in St. Louis – is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Services.
Whole genome sequencing may guide blood cancer treatment
For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes.
Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three decades.
Now, a new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing. In addition, results can be returned to patients in just a few days, making whole genome sequencing a potentially viable approach for determining the best treatment regimen for a particular patien
Sequencing results returned in a few days; costs similar to conventional testing
A new study from Washington University School of Medicine shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for blood cancers, such as acute myeloid leukemia and myelodysplastic syndrome. (Photo: Getty Images)
March 10, 2021 SHARE
For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes. Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three decades.
Promising role for whole genome sequencing in guiding blood cancer treatment – Washington University School of Medicine in St. Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.